Evidence map›Paper›PMID 39234563›Full record

ArticleFrontiers in cell and developmental biology2024

Inducible degradation-coupled phosphoproteomics identifies PP2A

Andrew G DeMarco, Marcella G Dibble, Mark C Hall

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Andrew G DeMarcoDepartment of Biochemistry, Purdue University, West Lafayette, IN, United States.
Marcella G DibbleDepartment of Biochemistry, Purdue University, West Lafayette, IN, United States.
Mark C HallDepartment of Biochemistry, Purdue University, West Lafayette, IN, United States.

Funding

Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI ANDREW D MESECAR · 1985 to 2026
$43.4M
Quality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2M
Cdc14 phosphatase - novel roles in drug resistance, virulence, and the response to cell wall stress in fungal pathogensR01AI168050 · NIAID · PURDUE UNIVERSITY · PI Mark C Hall · 2023 to 2026
$2.4M
Development and application of auxin-inducible degradation in Candida pathogensR21AI174123 · NIAID · PURDUE UNIVERSITY · PI HALL, MARK C · 2023 to 2024
$423k
NCATS NIH HHS UL1 TR002529NCI NIH HHS P30 CA023168NIAID NIH HHS R01 AI168050NIAID NIH HHS R21 AI174123
6 · The paper itself

Abstract

Introduction: Reversible protein phosphorylation is an abundant post-translational modification dynamically regulated by opposing kinases and phosphatases. Protein phosphorylation has been extensively studied in cell division, where waves of cyclin-dependent kinase activity, peaking in mitosis, drive the sequential stages of the cell cycle. Here we developed and employed a strategy to specifically probe kinase or phosphatase substrates at desired times or experimental conditions in the model organism Methods: We combined auxin-inducible degradation (AID) with mass spectrometry-based phosphoproteomics, which allowed us to arrest physiologically normal cultures in mitosis prior to rapid phosphatase degradation and phosphoproteome analysis. Results and discussion: Our results revealed that protein phosphatase 2A coupled with its B56 regulatory subunit, Rts1 (PP2A

Indexed as

auxin-inducible degradationB56eisosomeinducible protein degradationphosphatasephosphoproteomicsPP2ARts1

Identifiers

PMID39234563
PMCPMC11371571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.